PR Newswire BiotechnologyCodex · 实盘不做把握 8/10
北京时间·🕒 发布 20:21:00时区推断·⟳ 抓取 20:26:19·⚡ 决策 07-28 20:27:01 +42s·91.0 天前
CORE Biomedicine 获得卫材多个临床前肿瘤项目全球独家授权
本次只是卫材将多个临床前肿瘤项目授权给私营 CORE Biomedicine，未披露首付款、里程碑、分成或商业化时间表。
📄 原文PR Newswire Biotechnology↗ 原文
CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-…
不做 卫材（4523.JP）
未披露金额且资产仍为临床前项目，对卫材短期收入和利润没有可量化增量；CORE Biomedicine 为私营公司不可交易，因此不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是卫材将多个临床前肿瘤项目授权给私营 CORE Biomedicine，未披露首付款、里程碑、分成或商业化时间表。
- 项目仍处临床前阶段，短期无法形成对卫材收入、利润或估值的可量化增量。
- 可交易主体卫材为大型制药公司，未披露金额的早期管线授权不足以构成短线重定价催化。
主要风险
- 若后续补充披露高额首付款或明确临床资产价值，需要按新信息重新评估。
- CORE 为私营公司，无法直接交易授权受益方。
原文全文
展开原文 · 3,276 字
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to develop and commercialize multiple preclinical oncology programs.
The licensed programs were originally discovered through research activities conducted by Eisai and its affiliates. CORE Biomedicine was established by experienced oncology drug development leaders to advance these innovative programs for patients with cancer worldwide.
Under the agreement, CORE has obtained exclusive, global rights to certain preclinical oncology programs that target key molecular drivers of various cancers. The licensed portfolio includes multiple programs spanning distinct targets and biological pathways. Together, these assets provide CORE with a broad foundation to build a next-generation precision medicine company focused on translating deep cancer biology into transformative therapies for patients.
"CORE was created to advance an exceptional portfolio of oncology programs grounded in deep cancer biology, precision medicine and lineage therapeutics," said Dr. Douglas McMillin, Co-Founder and Head of Business Development of CORE Biomedicine. "We believe these programs have tremendous potential to address significant unmet medical needs across multiple cancers, and we are committed to advancing them efficiently toward the clinic and ultimately to patients."
CORE is advancing multiple precision oncology programs to clinical development designed to deliver transformative therapies for patients with unmet medical need. The agreement enables the continued advancement of innovative oncology programs through CORE's dedicated development strategy and commitment to precision medicine.
About CORE Biomedicine
CORE Biomedicine is an innovative drug discovery company developing transformative precision medicines for broader populations of cancer patients focusing on lineage biology. The company is advancing a portfolio of innovative oncology programs and leverages deep expertise in cancer biology, precision medicine, and drug development to bring novel therapies to patients worldwide. The company operates in the United States, Japan and China.
About Eisai
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Forward-Looking Statements
This press release contains forward-looking statements regarding the development and commercialization of investigational product candidates. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.
SOURCE CORE Biomedicine
The licensed programs were originally discovered through research activities conducted by Eisai and its affiliates. CORE Biomedicine was established by experienced oncology drug development leaders to advance these innovative programs for patients with cancer worldwide.
Under the agreement, CORE has obtained exclusive, global rights to certain preclinical oncology programs that target key molecular drivers of various cancers. The licensed portfolio includes multiple programs spanning distinct targets and biological pathways. Together, these assets provide CORE with a broad foundation to build a next-generation precision medicine company focused on translating deep cancer biology into transformative therapies for patients.
"CORE was created to advance an exceptional portfolio of oncology programs grounded in deep cancer biology, precision medicine and lineage therapeutics," said Dr. Douglas McMillin, Co-Founder and Head of Business Development of CORE Biomedicine. "We believe these programs have tremendous potential to address significant unmet medical needs across multiple cancers, and we are committed to advancing them efficiently toward the clinic and ultimately to patients."
CORE is advancing multiple precision oncology programs to clinical development designed to deliver transformative therapies for patients with unmet medical need. The agreement enables the continued advancement of innovative oncology programs through CORE's dedicated development strategy and commitment to precision medicine.
About CORE Biomedicine
CORE Biomedicine is an innovative drug discovery company developing transformative precision medicines for broader populations of cancer patients focusing on lineage biology. The company is advancing a portfolio of innovative oncology programs and leverages deep expertise in cancer biology, precision medicine, and drug development to bring novel therapies to patients worldwide. The company operates in the United States, Japan and China.
About Eisai
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Forward-Looking Statements
This press release contains forward-looking statements regarding the development and commercialization of investigational product candidates. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.
SOURCE CORE Biomedicine
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。